Jennison Associates Portfolio holdings
Jennison Associates is the research-driven stock investing arm of PGIM, the asset management business of Prudential Financial. It started in 1969, through a predecessor company, managing growth stock accounts of large U.S. companies, mainly for large institutions, and Prudential bought it in 1985. Its growth stock investors believe that rising earnings and cash flow drive share prices, and it also runs long-only and long/short portfolios of global healthcare companies. It began advising mutual funds in 1990 and also manages bond portfolios, choosing investments through its own company-by-company research. Its clients include pension plans, public employee retirement systems, foundations and endowments.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$1.27B |
| 2 |
Sandisk
SNDK
|
+$674M |
| 3 |
Credo Technology Group
CRDO
|
+$476M |
| 4 |
Nebius Group N.V.
NBIS
|
+$452M |
| 5 |
Vertiv
VRT
|
+$420M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.98B |
| 2 |
Amazon
AMZN
|
+$1.25B |
| 3 |
Shopify
SHOP
|
+$1.08B |
| 4 |
Edwards Lifesciences
EW
|
+$1.07B |
| 5 |
Microsoft
MSFT
|
+$630M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.11% |
| 2 | Communication Services | 13.94% |
| 3 | Consumer Discretionary | 10.64% |
| 4 | Industrials | 9.08% |
| 5 | Healthcare | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
PPL Corp
PPL
$26.9B
| $127M | 0.08% |
3,499,110
+1,195,128
| +52% | +$44.2M |
2022 Q3
15 quarters
|
|
127
AstraZeneca
AZN
$286B
| $126M | 0.08% |
666,497
+2,552
| +0.4% | +$480K |
2018 Q2
32 quarters
|
|
128
Comfort Systems
FIX
$38.9B
| $126M | 0.08% |
63,477
+33,590
| +112% | +$61M |
2024 Q2
8 quarters
|
|
129
Rush Enterprises Class A
RUSHA
$5.25B
| $124M | 0.07% |
2,549,414
+867,239
| +52% | +$40.8M |
2020 Q3
23 quarters
|
|
130
Nordson
NDSN
$18.1B
| $120M | 0.07% |
398,533
+10,423
| +3% | +$2.96M |
2025 Q3
3 quarters
|
|
131
Applied Materials
AMAT
$294B
| $120M | 0.07% |
165,784
-126,503
| -43% | -$58.4M |
2023 Q1
13 quarters
|
|
132
Hexcel
HXL
$6.02B
| $119M | 0.07% |
1,193,356
+9,040
| +0.8% | +$819K |
2022 Q4
14 quarters
|
|
133
Gates Industrial Corp
GTES
$6.38B
| $118M | 0.07% |
4,228,443
+324,196
| +8% | +$8.33M |
2024 Q1
9 quarters
|
|
134
Kirby Corp
KEX
$6.75B
| $118M | 0.07% |
865,097
+107,068
| +14% | +$15.3M |
2022 Q1
17 quarters
|
|
135
Caterpillar
CAT
$275B
| $116M | 0.07% |
109,244
-20,662
| -16% | -$18.2M |
2020 Q4
22 quarters
|
|
136
CMS Energy
CMS
$22.1B
| $116M | 0.07% |
1,517,533
-70,126
| -4% | -$5.26M |
2013 Q2
52 quarters
|
|
137
Northrop Grumman
NOC
$78.2B
| $115M | 0.07% |
226,563
-108,502
| -32% | -$62.6M |
2025 Q1
5 quarters
|
|
138
Ameris Bancorp
ABCB
$5.55B
| $115M | 0.07% |
1,274,893
-115,119
| -8% | -$9.8M |
2024 Q4
6 quarters
|
|
139
RBC Bearings
RBC
$15.4B
| $114M | 0.07% |
176,861
-2,478
| -1% | -$1.48M |
2023 Q4
10 quarters
|
|
140
Marsh
MRSH
$98.8B
| $114M | 0.07% |
683,273
+460,679
| +207% | +$77M |
2020 Q1
25 quarters
|
|
141
Danaher
DHR
$164B
| $114M | 0.07% |
597,780
+227,057
| +61% | +$41.2M |
2025 Q1
5 quarters
|
|
142
AXIS Capital
AXS
$7.8B
| $114M | 0.07% |
1,057,270
-14,617
| -1% | -$1.47M |
2019 Q3
27 quarters
|
|
143
PepsiCo
PEP
$198B
| $114M | 0.07% |
838,558
+309,429
| +58% | +$46.3M |
2019 Q1
29 quarters
|
|
144
Rockwell Automation
ROK
$44.2B
| $113M | 0.07% |
228,111
-21,974
| -9% | -$9.6M |
2025 Q2
4 quarters
|
|
145
Churchill Downs
CHDN
$6.84B
| $113M | 0.07% |
1,257,575
+122,857
| +11% | +$11M |
2022 Q3
15 quarters
|
|
146
Valero Energy
VLO
$106B
| $113M | 0.07% |
432,725
+19,288
| +5% | +$4.75M |
2014 Q3
47 quarters
|
|
147
WESCO International
WCC
$15.7B
| $111M | 0.07% |
322,583
+3,418
| +1% | +$1.16M |
2024 Q4
6 quarters
|
|
148
Dorman Products
DORM
$3.9B
| $111M | 0.07% |
814,857
-11,428
| -1% | -$1.35M |
2023 Q3
11 quarters
|
|
149
Elanco Animal Health
ELAN
$13.4B
| $111M | 0.07% |
4,508,395
+1,387,730
| +44% | +$32.1M |
2024 Q2
8 quarters
|
|
150
Arcutis Biotherapeutics
ARQT
$3.57B
| $111M | 0.07% |
4,219,058
-761,712
| -15% | -$17.7M |
2022 Q2
16 quarters
|
|
Similar funds
Jennison Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Jennison Associates held 641 positions worth $167B, up 15% from $145B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Jennison Associates withdrew a net $6.22B in Q2 2026, closing 74 positions and reducing 282 holdings. Its most notable exit was Gilead Sciences, an estimated $176M position sold in full.
By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 39% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in SpaceX worth $1.27B.
- Jennison Associates's largest Q2 2026 buy was SpaceX: 7,448,891 shares worth $1.27B.
- Jennison Associates added most to Credo Technology Group in Q2 2026, an estimated $476M increase.
- Jennison Associates's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.98B.
- Jennison Associates fully exited Gilead Sciences in Q2 2026, selling an estimated $176M.
- Jennison Associates's ten largest holdings make up 45% of its $167B portfolio in Q2 2026.
- Jennison Associates opened 79 new positions and closed 74 in Q2 2026.
- Jennison Associates's portfolio value rose 15% quarter-over-quarter to $167B.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.